WO2016185069A1 - Una composición farmacéutica antiviral de uso tópico - Google Patents
Una composición farmacéutica antiviral de uso tópico Download PDFInfo
- Publication number
- WO2016185069A1 WO2016185069A1 PCT/ES2016/070365 ES2016070365W WO2016185069A1 WO 2016185069 A1 WO2016185069 A1 WO 2016185069A1 ES 2016070365 W ES2016070365 W ES 2016070365W WO 2016185069 A1 WO2016185069 A1 WO 2016185069A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- weight
- concentration
- cationic
- facilitator
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Definitions
- Type 1 infections often occur during childhood or childhood. The infection is caused by direct contact with infected people.
- the herpes simplex virus type 1 generates as a consequence of the infection, the appearance of small, clear, fluid-filled blisters that occur most frequently at the labial level, while on the face they appear as swollen and painful structures that heal spontaneously afterwards about 5 to 7 days without leaving new scars, but it is known that these infections tend to reappear over time.
- Herpes Type 1 causes infections in the genital area. It can also develop in wounds on the skin and mucous membranes.
- idoxuridine in the early 1960s, those compounds containing zinc salts, and 75% dimethylsulfoxide solutions and more recently antivirals such as acyclovir, ganciclovir, etc.
- the anti-viral compositions of the present invention can be applied topically in the areas of interest in an infected subject, such as in the skin and / or mucous membranes.
- the anti-viral compositions of the present invention optionally contain a carrier or carrier, such as a bioadhesive polymer, to keep the two active ingredients on the viral lesion to be treated for longer.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2017014162A MX2017014162A (es) | 2015-05-15 | 2016-05-13 | Una composicion farmaceutica antiviral de uso topico. |
EP16795937.8A EP3295934B1 (en) | 2015-05-15 | 2016-05-13 | Antiviral pharmaceutical composition for topical use |
ES16795937T ES2915824T3 (es) | 2015-05-15 | 2016-05-13 | Composición farmacéutica antiviral de uso tópico |
US15/573,901 US10478452B2 (en) | 2015-05-15 | 2016-05-13 | Antiviral pharmaceutical composition for topical use |
BR112017024399-7A BR112017024399B1 (pt) | 2015-05-15 | 2016-05-13 | Composição farmacêutica antiviral de uso tópico |
CONC2017/0011297A CO2017011297A2 (es) | 2015-05-15 | 2017-11-02 | Una composición farmacéutica antiviral de uso tópico |
IL255635A IL255635A (en) | 2015-05-15 | 2017-11-13 | Antiviral pharmaceutical composition for topical use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP20150101519 | 2015-05-15 | ||
ARP150101519A AR100459A1 (es) | 2015-05-15 | 2015-05-15 | Una composición farmacéutica antiviral de uso tópico |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016185069A1 true WO2016185069A1 (es) | 2016-11-24 |
Family
ID=57319498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2016/070365 WO2016185069A1 (es) | 2015-05-15 | 2016-05-13 | Una composición farmacéutica antiviral de uso tópico |
Country Status (11)
Country | Link |
---|---|
US (1) | US10478452B2 (es) |
EP (1) | EP3295934B1 (es) |
AR (1) | AR100459A1 (es) |
BR (1) | BR112017024399B1 (es) |
CL (1) | CL2017002796A1 (es) |
CO (1) | CO2017011297A2 (es) |
ES (1) | ES2915824T3 (es) |
IL (1) | IL255635A (es) |
MX (1) | MX2017014162A (es) |
PE (1) | PE20180396A1 (es) |
WO (1) | WO2016185069A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022219944A1 (ja) * | 2021-04-16 | 2022-10-20 | 株式会社日本触媒 | 抗コロナウイルス剤 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3743727A (en) * | 1970-11-16 | 1973-07-03 | Crown Zellerbach Corp | Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide |
WO2005074947A2 (en) * | 2003-12-10 | 2005-08-18 | Sd Pharmaceuticals, Inc. | Anti-viral pharmaceutical compositions |
EP1762226A2 (en) * | 2005-07-22 | 2007-03-14 | Mipharm S.P.A. | Topical formulations in the form of gels containing acyclovir and lidocaine as active ingredients |
US20070184013A1 (en) * | 2006-02-09 | 2007-08-09 | Marcia Snyder | Antiviral method |
US20140328895A1 (en) * | 2011-03-29 | 2014-11-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Film-forming composition for a ph-dependant sustained release of the active agent |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4902720A (en) * | 1983-01-10 | 1990-02-20 | Baldone Joseph A | Treatment of virus infections with quaternary ammonium compounds |
US5160737A (en) * | 1988-05-03 | 1992-11-03 | Perio Products Ltd. | Liquid polymer composition, and method of use |
BRPI0014271B1 (pt) * | 1999-09-24 | 2021-06-22 | Janssen Pharmaceutica N.V. | Partícula consistindo em uma dispersão de sólidos, uso da dita partícula, dispersão de sólidos, forma de dosagem farmacêutica, bem como processos de preparação de dita partícula, dispersão e forma de dosagem |
US6855341B2 (en) | 2002-11-04 | 2005-02-15 | Jeffrey B. Smith | Anti-viral compositions and methods of making and using the anti-viral compositions |
US7883487B2 (en) * | 2008-06-16 | 2011-02-08 | Shantha Totada R | Transdermal local anesthetic patch with injection port |
-
2015
- 2015-05-15 AR ARP150101519A patent/AR100459A1/es unknown
-
2016
- 2016-05-13 PE PE2017002343A patent/PE20180396A1/es unknown
- 2016-05-13 EP EP16795937.8A patent/EP3295934B1/en active Active
- 2016-05-13 BR BR112017024399-7A patent/BR112017024399B1/pt active IP Right Grant
- 2016-05-13 ES ES16795937T patent/ES2915824T3/es active Active
- 2016-05-13 WO PCT/ES2016/070365 patent/WO2016185069A1/es active Application Filing
- 2016-05-13 MX MX2017014162A patent/MX2017014162A/es unknown
- 2016-05-13 US US15/573,901 patent/US10478452B2/en active Active
-
2017
- 2017-11-02 CO CONC2017/0011297A patent/CO2017011297A2/es unknown
- 2017-11-06 CL CL2017002796A patent/CL2017002796A1/es unknown
- 2017-11-13 IL IL255635A patent/IL255635A/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3743727A (en) * | 1970-11-16 | 1973-07-03 | Crown Zellerbach Corp | Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide |
WO2005074947A2 (en) * | 2003-12-10 | 2005-08-18 | Sd Pharmaceuticals, Inc. | Anti-viral pharmaceutical compositions |
EP1762226A2 (en) * | 2005-07-22 | 2007-03-14 | Mipharm S.P.A. | Topical formulations in the form of gels containing acyclovir and lidocaine as active ingredients |
US20070184013A1 (en) * | 2006-02-09 | 2007-08-09 | Marcia Snyder | Antiviral method |
US20140328895A1 (en) * | 2011-03-29 | 2014-11-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Film-forming composition for a ph-dependant sustained release of the active agent |
Non-Patent Citations (1)
Title |
---|
See also references of EP3295934A4 * |
Also Published As
Publication number | Publication date |
---|---|
MX2017014162A (es) | 2018-06-20 |
US20180250327A1 (en) | 2018-09-06 |
CO2017011297A2 (es) | 2018-01-31 |
BR112017024399A2 (pt) | 2019-02-05 |
IL255635A (en) | 2018-01-31 |
EP3295934A1 (en) | 2018-03-21 |
EP3295934B1 (en) | 2022-03-02 |
ES2915824T3 (es) | 2022-06-27 |
EP3295934A4 (en) | 2019-01-02 |
BR112017024399B1 (pt) | 2022-06-07 |
CL2017002796A1 (es) | 2018-07-13 |
AR100459A1 (es) | 2016-10-05 |
PE20180396A1 (es) | 2018-02-28 |
US10478452B2 (en) | 2019-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2396719T3 (es) | Composición para tratamiento de lesiones en la piel | |
US8853272B2 (en) | Method for treating an inflammation or lesion caused by a virus | |
ES2236324T3 (es) | Composiciones farmaceuticas para el tratamiento de mucositis, estomatitis y sindrome de behcet. | |
ES2402864T3 (es) | Prevención de infección por VIH con TMC278 | |
UY27875A1 (es) | Prodrogas 2 ' y 3 ' de nucleósidos modificados para tratar flaviviridae | |
ES2171590T7 (es) | Preparación farmacéutica para el tratamiento de rinitis agudas que contiene un simpaticomimético y pantotenol y/o ácido pantoténico | |
ES2302691T5 (es) | Formulaciones antihelmínticas. | |
ITRM20060163A1 (it) | Composizione spray ad uso topico per il tratamento e la prevenzione delle infezioni labiali da herpes simplex | |
ES2915824T3 (es) | Composición farmacéutica antiviral de uso tópico | |
ES2356774T3 (es) | Composición farmacéutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpética. | |
WO1993000114A1 (en) | Topical composition enhancing healing of herpes lesions | |
ES2371739T3 (es) | Uso de corrinoides para su aplicación en enfermedades de la piel. | |
DK2374461T3 (en) | Piroxicam for the prophylactic and therapeutic treatment of herpes infections | |
ES2615236T3 (es) | Tratamiento de infecciones víricas | |
BR112020003735A2 (pt) | método e composição para tratar, prevenir ou reduzir epidemias virais de ocorrência única ou recorrentes, suprimir o desenvolvimento ou o crescimento de infecções virais crônicas, ou para prevenir ou tratar infecções virais | |
ES2230747T3 (es) | Utilizacion de triclosan para la prevencion y el tratamiento de la mocositis. | |
NZ606177A (en) | Compositions for the treatment of actinic keratosis | |
ES2734269T3 (es) | Composición que comprende carragenina tipo iota contra conjuntivitis viral | |
ES2808864T3 (es) | Método para tratar enfermedades recurrentes de la piel y la membrana mucosa provocadas por HSV-1 y HSV-2 | |
ES2719054T3 (es) | Tratamiento de lesiones cutáneas asociadas a enfermedades autoinmunitarias e inflamatorias con el compuesto de arsénico As2O5 | |
BR112019018998A2 (pt) | tratamento de sintomas de herpes simples na pele e membrana mucosa de mamíferos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16795937 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 002343-2017 Country of ref document: PE |
|
WWE | Wipo information: entry into national phase |
Ref document number: NC2017/0011297 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2017/014162 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 255635 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15573901 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016795937 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017024399 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112017024399 Country of ref document: BR Free format text: COMO FORAM SOLICITADOS 2 (DOIS) SERVICOS ATRAVES DA PETICAO 870170094908, DE 06/12/2017, E, DE ACORDO COM A RESOLUCAO NO189/2017 DEVEM SER PAGAS RETRIBUICOES ESPECIFICAS PARA CADA UM DOS SERVICOS SOLICITADOS, SE FAZ NECESSARIA A COMPLEMENTACAO DO PAGAMENTO, ALEM DO RECOLHIMENTO DA GUIA RELATIVA A ESTA EXIGENCIA. |
|
ENP | Entry into the national phase |
Ref document number: 112017024399 Country of ref document: BR Kind code of ref document: A2 Effective date: 20171113 |